We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adults with a loss-of-function mutation in the MC4R gene ...
Palatin (PTN) Technologies announced that preclinical data from the Company’s melanocortin 4 receptor, or MC4R, selective PL7737 obesity program will be highlighted in a poster presentation at ...
CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
CRANBURY, N.J., March 31, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
Food intake and energy expenditure were thought to be simultaneously controlled by the same group of neurons, but now new evidence shows that they are independently regulated by an anatomically ...
Credit: Rhythm Pharmaceuticals The approval for younger patients was based on data from the 1-year, open-label, phase 3 VENTURE trial. Results from the VENTURE trial showed significant reductions in ...
The MarketWatch News Department was not involved in the creation of this content. MONTREAL, March 19, 2026 /PRNewswire/ -- Congruence Therapeutics today announced that the first participant has been ...
Primary endpoint met in the 8-week treatment study (highly statistically significant). Co-administered group had a 4.4% reduction in weight compared to 1.6% for the placebo group (p<0.0001). Primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results